CN117224566A - Cordycepin compound preparation, preparation method thereof and application thereof in preparation of sports fatigue improving products - Google Patents
Cordycepin compound preparation, preparation method thereof and application thereof in preparation of sports fatigue improving products Download PDFInfo
- Publication number
- CN117224566A CN117224566A CN202311344872.5A CN202311344872A CN117224566A CN 117224566 A CN117224566 A CN 117224566A CN 202311344872 A CN202311344872 A CN 202311344872A CN 117224566 A CN117224566 A CN 117224566A
- Authority
- CN
- China
- Prior art keywords
- cordycepin
- preparation
- parts
- content
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 title claims abstract description 130
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 238000002360 preparation method Methods 0.000 title claims abstract description 104
- -1 Cordycepin compound Chemical class 0.000 title claims abstract description 59
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims abstract description 70
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 54
- 239000005017 polysaccharide Substances 0.000 claims abstract description 54
- 150000004676 glycans Chemical class 0.000 claims abstract description 53
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 37
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 37
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 37
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 30
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 30
- 241000190633 Cordyceps Species 0.000 claims abstract description 24
- 230000037080 exercise endurance Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 32
- 239000002131 composite material Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 57
- 210000002966 serum Anatomy 0.000 abstract description 48
- 206010016256 fatigue Diseases 0.000 abstract description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 36
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 28
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 22
- 230000009182 swimming Effects 0.000 abstract description 21
- 229920002527 Glycogen Polymers 0.000 abstract description 19
- 229940096919 glycogen Drugs 0.000 abstract description 19
- 239000004310 lactic acid Substances 0.000 abstract description 18
- 235000014655 lactic acid Nutrition 0.000 abstract description 18
- 229940109239 creatinine Drugs 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 14
- 102000001554 Hemoglobins Human genes 0.000 abstract description 12
- 108010054147 Hemoglobins Proteins 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 12
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 11
- 229960003604 testosterone Drugs 0.000 abstract description 11
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 abstract description 10
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 36
- 230000000052 comparative effect Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241001264174 Cordyceps militaris Species 0.000 description 12
- 238000005303 weighing Methods 0.000 description 11
- 230000002929 anti-fatigue Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000008223 sterile water Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 9
- 244000131316 Panax pseudoginseng Species 0.000 description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 3
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- 241000993291 Armillariella Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of natural medicines, and particularly relates to a cordycepin compound preparation, a preparation method thereof and application thereof in preparation of products for improving sports fatigue. A cordycepin compound preparation comprises the following components in parts by weight: 1-50 parts of cordycepin; 1-100 parts of cordyceps polysaccharide; 1-50 parts of ginsenoside; 1-80 parts of maca polysaccharide. The cordycepin compound preparation can prolong the swimming time of mice, reduce the serum urea nitrogen content, serum lactic acid content, serum creatinine content and serum corticosterone content of the mice, and increase the hemoglobin content, liver glycogen content, myoglycogen content and serum testosterone content of the mice, thereby improving fatigue symptoms and improving exercise endurance of organisms.
Description
Technical Field
The invention belongs to the technical field of natural medicines, and particularly relates to a cordycepin compound preparation, a preparation method thereof and application thereof in preparation of products for improving sports fatigue.
Background
Fatigue refers to the phenomenon in which the body is unable to maintain its function at a specific level and/or to maintain a predetermined intensity of movement during its physiology. If the fatigue cannot be eliminated in time after the fatigue is generated, the fatigue can be further developed into 'overstrain', so that endocrine disturbance, immunity decline and even organic lesions occur in the organism. Thus, fatigue has become a major factor in today's society threatening the health of humans. There are some strategies for relieving fatigue such as dietary supplements like taurine, creatine, l-carnitine, ginseng, rhodiola rosea, etc. However, its application is limited due to poor relief effect, large side effects, high cost, and the like. Therefore, it is essential to find more effective drug candidates with fewer side effects to alleviate fatigue.
Cordyceps militaris is a rare traditional Chinese medicine fungus containing bioactive substances such as cordycepin, mannitol, polysaccharide wheat, and cholesterol, and has been widely used in China for treating various diseases in circulatory system, immunity, respiration and glandular system, preventing aging, etc. The study shows that the cordycepin content of the cordyceps militaris is obviously higher than that of other fungi known at present, for the same cordyceps militaris, the cordycepin content of the fruiting body is obviously higher than that of hyphae. Cordycepin is also called 3-deoxyadenosine, is a natural product obtained by separating Cordyceps militaris, and has a structure very similar to adenosine, so that cordycepin is considered as a very effective bioactive component, and modern pharmacological research has shown that the cordycepin has wide physiological function regulating effects of immune system, nervous system, motor system, endocrine system and the like. The past researches show that the cordyceps militaris has the effect of relieving fatigue, can improve the secretion composition of neurotransmitters in sports fatigue mice, and the active ingredient cordycepin in the cordyceps militaris has obvious anti-fatigue effect, and the mechanism of the cordycepin is possibly related to energy consumption, metabolic processes, oxidative stress damage alleviation and neurotransmitter concentration change.
Ginsenoside is the main active ingredient of ginseng, pseudo-ginseng and American ginseng, is also the main ingredient of ginseng extract, has extremely strong pharmacological activity, and the content is an important evaluation index of the intrinsic quality of ginseng. Modern pharmacological research shows that ginsenoside can up regulate the transcription of neurotrophic factor mRNA by promoting the expression of hippocampal nerve growth factor and brain-derived neurotrophic factor mRNA in hippocampus, promote the repair of rat nerve injury, and relieve central fatigue caused by postoperative fatigue syndrome through nerve tissue regeneration and repair.
Maca is a Lepidium genus of Brassicaceae, belongs to annual or biennial herbaceous plants, and is produced in mountain areas with high altitude and severe ecological environment in south America. Maca is originally used as food by Peruvian, and the edible part is mainly the root. Research shows that the maca contains multiple nutritional components such as polysaccharide, polypeptide, branched chain amino acid, mineral elements and the like, and has good effects on improving human metabolism, sexual function, immunity, fatigue resistance and the like; wherein the active ingredient maca polysaccharide can relieve fatigue symptoms and show dose dependence. The mechanism of analysis of anti-fatigue activity may be associated with reduced production of oxidative free radicals, as well as improving disruption of the integrity of the myofiber and mitochondrial membrane biofilms and cell metabolic disorders.
In the prior art, the anti-fatigue drug has great toxic and side effects, so the development of an efficient anti-fatigue product without obvious side effects on human bodies has great significance.
Disclosure of Invention
The invention aims to solve the technical problem of providing a cordycepin compound preparation aiming at the defects of the prior art.
Further, the invention also provides a preparation method of the cordycepin composite preparation.
Furthermore, the invention also solves the technical problem of providing the application of the cordycepin compound preparation in preparing products for improving sports fatigue.
In order to solve the technical problems, the invention adopts the following technical scheme:
in order to solve the first technical problem, the invention discloses a cordycepin compound preparation which comprises the following components in parts by weight:
1-50 parts of cordycepin;
1-100 parts of cordyceps polysaccharide;
1-50 parts of ginsenoside;
1-80 parts of maca polysaccharide.
In some embodiments, preferably, the cordycepin compound preparation comprises the following components in parts by weight:
10-40 parts of cordycepin;
40-80 parts of cordyceps polysaccharide;
10-40 parts of ginsenoside;
20-60 parts of maca polysaccharide.
In some embodiments, it is further preferred that the cordycepin compound preparation comprises the following components in parts by weight:
20 parts of cordycepin;
60 parts of cordyceps polysaccharide;
20 parts of ginsenoside;
40 parts of maca polysaccharide.
In some embodiments, it is further preferred that the cordycepin compound preparation comprises the following components in parts by weight:
cordycepin 20mg;
60mg of cordyceps polysaccharide;
20mg of ginsenoside;
40mg of maca polysaccharide.
In some embodiments, the cordycepin is greater than 98% pure.
In some embodiments, the Cordyceps sinensis polysaccharide has a purity of greater than 98%.
In some embodiments, the ginsenoside has a purity of greater than 98%.
In some embodiments, the maca polysaccharide is greater than 98% pure.
Wherein, the cordycepin is extracted from wild Cordyceps militaris and/or artificially cultured Cordyceps militaris.
Wherein the Cordyceps polysaccharide is extracted from artificially cultured Cordyceps militaris.
Wherein the ginsenoside is extracted from Ginseng radix.
Wherein, the maca polysaccharide is extracted from maca.
In some embodiments, the dosage form of the cordycepin compound preparation is any one of powder, capsule, pill, granule, tablet and oral liquid preparation.
In order to solve the second technical problem, the invention further discloses a preparation method of the cordycepin composite preparation, which comprises the steps of mixing cordycepin, cordyceps polysaccharide, ginsenoside and maca polysaccharide, adding one or more pharmaceutically acceptable auxiliary materials, and preparing the cordycepin composite preparation by a conventional preparation method of a medicinal preparation.
The application of the cordycepin compound preparation in preparing products for improving sports fatigue is also within the protection scope of the invention.
The application of the cordycepin compound preparation in preparing products for improving exercise endurance and promoting exercise recovery is also within the protection scope of the invention.
Specifically, the product is any one of functional food, medicine and health care product.
Wherein the purity or the content is mass percent.
The invention is characterized in that: cordycepin achieves remarkable anti-fatigue effects by removing metabolic waste and increasing energy reserves, and can improve the anti-fatigue capability of mice, reduce the level of lactic acid (LD), malondialdehyde (MDA) and urea nitrogen (BUN), increase glycogen content and improve the content of neurotransmitters related to central fatigue.
Cordyceps polysaccharide can prolong the time from exercise to fatigue, and can improve glycogen storage of organism after exhaustion exercise.
The ginsenoside can prolong the load swimming time of the mice, increase the content of hepatic glycogen in the body, reduce the accumulation of BUN in the body and the content of lactamase (BLA) in blood caused by sports fatigue, meanwhile, the influence of ginseng on the antioxidant related enzyme in the sports fatigue mice is not obvious, fatigue generated after the forced swimming of the mice is loaded can cause the reduction of the dopamine level in the brains of the mice, and the fatigue is related to the reduction of the expression and the phosphorylation level of tyrosine hydroxylase, and the ginsenoside can increase the expression and the phosphorylation level of the tyrosine hydroxylase, improve the dopamine level in the brains, obviously prolong the load swimming time of the mice and play the role of resisting fatigue by activating signal paths such as PKA alpha, ERK1/2, akt, alpha-synapsin and the like.
The maca polysaccharide can remarkably increase the load swimming time, improve the activity of superoxide dismutase (SOD), reduce the MDA content and free radical accumulation to relieve lipid peroxidation level, relieve fatigue symptoms and show dose dependence. The mechanism of anti-fatigue activity is associated with reduced production of oxidative free radicals and improved disruption of the integrity of the myofibrillar and mitochondrial membrane biofilms and cell metabolic disorders.
The cordycepin compound preparation has obvious effects of improving exercise endurance and promoting exercise recovery, and the cordycepin can regulate the nervous system of an organism to play an anti-fatigue role by improving the content of neurotransmitters related to central fatigue; cordyceps polysaccharide has the effects of improving exercise capacity by improving glycogen storage, and prolonging exercise time of body's exhaustion; the ginsenoside can increase the expression and phosphorylation level of tyrosine hydroxylase, improve the level of dopamine in brain, obviously prolong the load swimming time of mice and play an anti-fatigue role by activating signal paths such as PKA alpha, ERK1/2, akt, alpha-synapsin and the like; the fatigue symptom is relieved by reducing the generation of oxidation free radicals and improving the damage of the integrity of the myofiber membrane and the mitochondrial membrane biological membrane, the anti-fatigue activity of the maca polysaccharide is not obviously related to lactic acid metabolism, and the cordycepin and the ginsenoside can obviously improve the serum lactic acid of a fatigued mouse, and the four raw materials supplement each other, play roles in improving exercise endurance from different layers and promoting exercise recovery.
The beneficial effects are that:
(1) Compared with the traditional product for improving exercise endurance and promoting exercise recovery, the cordycepin compound preparation disclosed by the invention belongs to natural extracts, has no obvious side effect on human bodies, can be metabolized normally, and can effectively solve the problems of high toxic and side effects of drugs for improving exercise endurance and promoting exercise recovery in the prior art. The invention records the exhausted swimming time by carrying out pharmacodynamic analysis on the mice; the effects of the cordycepin compound preparation on improving the exercise tolerance of mice are comprehensively evaluated by detecting the contents of urea nitrogen (BUN), hemoglobin (HB), lactic acid (LD), creatinine (CRE), liver Glycogen (hepatoglycogen), myoglycogen (Muscle Glycogen), testosterone (T) and Corticosterone (CORT).
(2) The cordycepin compound preparation can prolong the swimming time of mice, reduce the serum urea nitrogen content, serum lactic acid content, serum creatinine content and serum corticosterone content of the mice, and increase the hemoglobin content, liver glycogen content, myoglycogen content and serum testosterone content of the mice, thereby improving fatigue symptoms and improving exercise endurance of organisms.
Drawings
The foregoing and/or other advantages of the invention will become more apparent from the following detailed description of the invention when taken in conjunction with the accompanying drawings and detailed description.
FIG. 1 is a statistical chart of the effect of cordycepin complex formulations with different component ratios on the swimming time of mice; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 2 is a statistical graph of the effect of cordycepin complex formulations of different component ratios on serum urea nitrogen in mice; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 3 is a statistical graph of the effect of cordycepin complex formulations of different composition ratios on mouse hemoglobin; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 4 is a statistical chart of the effect of cordycepin complex formulations of different component ratios on serum lactic acid of mice; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 5 is a statistical graph of the effect of cordycepin complex formulations of different component ratios on serum creatinine in mice; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 6 is a statistical chart of the effect of cordycepin complex formulations of different component ratios on liver glycogen of mice; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 7 is a statistical chart of the effect of cordycepin complex formulations of different component ratios on mouse myoglycogen; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 8 is a statistical graph of the effect of cordycepin complex formulations of different composition ratios on serum testosterone in mice; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
FIG. 9 is a statistical graph of the effect of cordycepin complex formulations of different component ratios on mouse serum corticosterone; wherein, compared with the blank control group, * P<0.05， ** P<0.01。
Detailed Description
The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials, cat#d4522, unless otherwise specified, are commercially available.
The cordycepin used in the embodiment of the invention has the purity of more than 98 percent and is extracted from artificially cultivated Cordyceps militaris.
The Cordyceps polysaccharide used in the embodiment of the invention has purity of more than 98 percent and is extracted from artificially cultivated Cordyceps militaris.
The ginsenoside used in the embodiment of the invention has the purity of more than 98 percent and is extracted from ginseng.
The maca polysaccharide used in the embodiment of the invention has the purity of more than 98 percent and is extracted from maca.
The purity of the maca total alkaloids used in the embodiment of the invention is more than 98%, the maca total alkaloids are extracted from maca, and the extraction method of the maca total alkaloids is as follows in reference to the prior art:
luozi, zhang Hong, zheng Hua, etc. the ultrasonic wave and microwave extraction of total alkaloids [ J ]. Food industry technology, 2011,32 (12): 354-358.DOI:10.13386/J. Issn1002-0306.2011.12.052.
The mice used in the examples of the present invention were SPF grade male ICR mice weighing 25-30 g purchased from the Armillariella oldhamiana breeding ground (animal pass number: SCXK 2020-0005) of Jiang Ningou in Nanjing.
Example 1: preparation of cordycepin composite preparation 1
Weighing cordycepin 10mg, cordyceps polysaccharide 60mg, ginsenoside 20mg and maca polysaccharide 40mg, dissolving in 10mL sterile water, and uniformly stirring to dissolve completely to obtain cordycepin compound preparation 1.
Comparative example 1: preparation of formulation A
Weighing cordycepin 10mg, cordyceps polysaccharide 60mg, and ginsenoside 20mg, dissolving in 10mL sterile water, and stirring thoroughly to obtain preparation A.
Comparative example 2: preparation of formulation B
Weighing cordycepin 10mg, ginsenoside 20mg and maca polysaccharide 40mg, dissolving in 10mL sterile water, and uniformly stirring to fully dissolve to obtain preparation B.
Comparative example 3: preparation of formulation C
Weighing Cordyceps polysaccharide 60mg, ginsenoside 20mg, and maca polysaccharide 40mg, dissolving in 10mL sterile water, and stirring thoroughly to obtain preparation C.
Comparative example 4: preparation of formulation D
Weighing cordycepin 10mg, cordyceps polysaccharide 60mg and maca polysaccharide 40mg, dissolving in 10mL sterile water, and stirring uniformly to dissolve completely to obtain preparation D.
Comparative example 5: preparation of formulation E
Weighing 80mg of artificially cultivated Cordyceps militaris powder, 20mg of ginseng powder and 40mg of maca powder, dissolving in 10mL of sterile water, uniformly stirring and fully dissolving to obtain a preparation E.
Comparative example 6: preparation of formulation F
Weighing cordycepin 20mg, cordyceps polysaccharide 60mg, ginsenoside 20mg and maca total alkaloids 40mg, dissolving in 10mL sterile water, and stirring completely to obtain preparation F.
Example 2: preparation of cordycepin compound preparation 2
Weighing cordycepin 20mg, cordyceps polysaccharide 60mg, ginsenoside 20mg and maca polysaccharide 40mg, dissolving in 10mL sterile water, and uniformly stirring to dissolve completely to obtain cordycepin compound preparation 2.
Example 3: preparation of cordycepin compound preparation 3
Weighing cordycepin 20mg, cordyceps polysaccharide 60mg, ginsenoside 10mg and maca polysaccharide 40mg, dissolving in 10mL sterile water, and uniformly stirring to dissolve completely to obtain cordycepin compound preparation 3.
Example 4: preparation of cordycepin compound preparation 4
Weighing cordycepin 20mg, cordyceps polysaccharide 60mg, ginsenoside 20mg, and maca polysaccharide 30mg, dissolving in 10mL sterile water, and stirring completely to obtain cordycepin compound preparation 4.
Example 5: influence of different cordycepin compound preparations on the swimming time of mice
1. Grouping and administration of mice
The number of SPF-grade male ICR mice is 110, and after one week of adaptive feeding, the mice are randomly divided into 11 groups (10 in each group) which are respectively a blank control group, an example 1 group, a comparative example 2 group, a comparative example 3 group, a comparative example 4 group, a comparative example 5 group, a comparative example 6 group, an example 2 group, an example 3 group and an example 4 group; wherein, example 1 group administration cordycepin complex formulation 1 (prepared in example 1), comparative example 1 group administration formulation a (prepared in example 1), comparative example 2 group administration formulation B (prepared in example 2), comparative example 3 group administration formulation C (prepared in example 3), comparative example 4 group administration formulation D (prepared in example 4), comparative example 5 group administration formulation E (prepared in example 5), comparative example 6 group administration formulation F (prepared in example 6), example 2 group administration cordycepin complex formulation 2 (prepared in example 2), example 3 group administration cordycepin complex formulation 3 (prepared in example 3), example 4 group administration cordycepin complex formulation 4 (prepared in example 4), the administration dose of cordycepin was 20mg/kg; the blank group was given an equivalent dose of physiological saline. The above groups were administered once daily by intragastric administration for 30 consecutive days.
2. Influence of different cordycepin complex formulations on the swimming time of mice:
after 2 weeks of dosing, all mice were trained for adaptive swimming every 4 days, 3 times on the day of training, 10min each time. After the last administration for 30min, 6 mice were randomly selected and placed in a swimming box with a water depth of 25cm and a water temperature of 25+ -1deg.C, and the mice were loaded with 6% of their weight in their tail. The time from the beginning of the load swimming of the mice to the time when the heads of the mice are submerged in the water for 7 seconds and cannot return to the water surface, namely the time of the forced swimming is recorded.
The average swimming time measurement results of 6 experimental mice in each group are shown in fig. 1, and the experimental results show that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the exhausted swimming time of the cordycepin compound preparation intervention group is prolonged, and the effects of the cordycepin compound preparations prepared in the examples 1-4 are obviously better than those of other comparative examples 1-6 after administration. Experimental results prove that the cordycepin compound preparation composed of four natural extracts of cordycepin, cordyceps polysaccharide, ginsenoside and maca polysaccharide has better effect, and in the groups of examples 1-4, the effect of the group of example 2 is more obvious, and better treatment effect (P < 0.01) is shown. The experimental results show that: the cordycepin compound preparation prepared by the invention can prolong the swimming time of mice and improve fatigue symptoms.
Example 6: influence of different weight portions of cordycepin composite preparations on biochemical indexes related to exercise tolerance of mice
After the last administration for 30min, mice (4 mice in each group) not subjected to the load swimming test were subjected to the load free swimming for 90min, after the swimming was finished for 60min, the eyeballs were taken out for blood collection, serum was separated, and then the mice were dissected to take the liver and gastrocnemius muscle. The method comprises the steps of adopting an anthrone-sulfuric acid method to measure liver Glycogen (Hepatic Glycogen) in liver and Muscle Glycogen (Muscle Glycogen) in gastrocnemius, adopting a urease method kit to measure serum urea nitrogen (BUN), adopting a lactic dehydrogenase colorimetric method kit to measure serum lactic acid (LD), adopting a colorimetric method kit to measure Hemoglobin (HB) in whole blood, adopting a creatinine test kit (chemical method, deproteinization) colorimetric method to measure Creatinine (CRE) in serum, adopting an enzyme-linked immunosorbent assay kit to measure testosterone (T) and Corticosterone (CORT) in serum, and comprehensively evaluating the improvement effect of a cordycepin compound preparation on the exercise tolerance of mice.
(1) The results of the average serum urea nitrogen (BUN) content measurements of 4 experimental mice in each group are shown in fig. 2, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, the serum urea nitrogen content of the cordycepin compound preparation intervention group is reduced compared with that of a blank control group, wherein the serum urea nitrogen content of the comparison 1-6 groups and the example 4 groups is obviously reduced (P < 0.05), the serum urea nitrogen content of the example 1 group, the example 2 group and the example 3 group is extremely obviously reduced (P < 0.01), the effect of the example 2 group is the best, and the results show that the cordycepin compound preparation can reduce the serum urea nitrogen content of mice and improve fatigue symptoms.
(2) The average hemoglobin content measurement results of 4 experimental mice in each group are shown in fig. 3, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the hemoglobin content of the cordycepin compound preparation intervention group is increased, wherein the hemoglobin content of the comparison example 1-6 groups and the example 1 group is significantly increased (P < 0.05), the hemoglobin content of the example 2 group, the example 3 group and the example 4 group is significantly increased (P < 0.01), and the effect of the example 2 group is optimal, so that the cordycepin compound preparation can increase the hemoglobin content of mice and improve fatigue symptoms.
(3) The average serum lactic acid content measurement results of 4 experimental mice in each group are shown in fig. 4, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the serum lactic acid content of the cordycepin compound preparation intervention group is reduced, wherein the serum lactic acid content of the comparison example 2-6 groups is obviously reduced (P < 0.05), the serum lactic acid content of the comparison example 1 group and the serum lactic acid content of the comparison example 1-4 groups are extremely obviously reduced (P < 0.01), and the serum lactic acid content of the comparison example 2 group is most reduced, so that the cordycepin compound preparation can reduce the serum lactic acid content of mice and improve fatigue symptoms.
(4) The average serum creatinine content measurement results of 4 experimental mice in each group are shown in fig. 5, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the serum creatinine content of the cordycepin compound preparation intervention group is reduced, wherein the serum creatinine content of the comparison examples 1-6 groups is obviously reduced (P < 0.05), the serum creatinine content of the examples 1-4 groups is extremely obviously reduced (P < 0.01), and the serum creatinine content of the example 2 group is most obviously reduced, so that the cordycepin compound preparation can reduce the serum creatinine content of mice and improve fatigue symptoms.
(5) The average hepatic glycogen content measurement results of 4 experimental mice in each group are shown in fig. 6, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the liver glycogen content of the cordycepin compound preparation intervention group is increased, wherein the liver glycogen content of the comparison example 2-6 groups is obviously increased (P < 0.05), the liver glycogen content of the comparison example 1 group and the liver glycogen content of the comparison example 1-4 groups are obviously increased (P < 0.01), and the effect of the comparison example 2 group is optimal, so that the result shows that the cordycepin compound preparation can increase the liver glycogen content of mice and improve fatigue symptoms.
(6) The average myoglycogen content measurement results of 4 experimental mice in each group are shown in fig. 7, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the myoglycogen content of the cordycepin compound preparation intervention group is increased, wherein the myoglycogen content of the comparison example 2-6 groups is obviously increased (P < 0.05), the myoglycogen content of the comparison example 1 group and the myoglycogen content of the comparison example 1-4 groups are extremely obviously increased (P < 0.01), and the effect of the comparison example 2 group is optimal, so that the result shows that the cordycepin compound preparation can increase the myoglycogen content of mice and improve fatigue symptoms.
(7) The average serum testosterone levels of 4 experimental mice in each group are shown in fig. 8, and the experimental results indicate that: after different cordycepin compound preparations are given for dry prognosis, the serum testosterone content of the cordycepin compound preparation intervention group is increased compared with that of a blank control group, wherein the serum testosterone content of the comparison example 1-6 groups is obviously increased (P < 0.05), the serum testosterone content of the example 1-4 groups is extremely obviously increased (P < 0.01), and the serum testosterone content of the example 2 group is most obviously increased, so that the cordycepin compound preparation can increase the serum testosterone content of mice and improve fatigue symptoms.
(8) The average serum corticosterone content measurement results of 4 experimental mice in each group are shown in fig. 9, and the experimental results show that: after different cordycepin compound preparations are given for dry prognosis, compared with a blank control group, the cordycepin compound preparation intervention group has extremely obvious reduction effect (P < 0.01) on the serum corticosterone content, wherein the reduction effect of the example 2 group is most obvious, and the result shows that the cordycepin compound preparation can reduce the serum corticosterone content of mice and improve fatigue symptoms.
The invention provides a cordycepin compound preparation, a preparation method thereof and an application method thereof in preparing products for improving sports fatigue, and particularly the method and the way for realizing the technical scheme are numerous, the above is only a preferred embodiment of the invention, and it should be pointed out that a plurality of improvements and modifications can be made by those skilled in the art without departing from the principle of the invention, and the improvements and modifications are also considered as the protection scope of the invention. The components not explicitly described in this embodiment can be implemented by using the prior art.
Claims (12)
1. The cordycepin composite preparation is characterized by comprising the following components in parts by weight:
1-50 parts of cordycepin;
1-100 parts of cordyceps polysaccharide;
1-50 parts of ginsenoside;
1-80 parts of maca polysaccharide.
2. The cordycepin composite preparation as claimed in claim 1, which is characterized by comprising the following components in parts by weight:
10-40 parts of cordycepin;
40-80 parts of cordyceps polysaccharide;
10-40 parts of ginsenoside;
20-60 parts of maca polysaccharide.
3. The cordycepin composite preparation as claimed in claim 1, which is characterized by comprising the following components in parts by weight:
20 parts of cordycepin;
60 parts of cordyceps polysaccharide;
20 parts of ginsenoside;
40 parts of maca polysaccharide.
4. The cordycepin composite preparation as claimed in claim 1, which is characterized by comprising the following components in parts by weight:
cordycepin 20mg;
60mg of cordyceps polysaccharide;
20mg of ginsenoside;
40mg of maca polysaccharide.
5. The cordycepin complex formulation of claim 1 wherein the cordycepin has a purity of greater than 98%.
6. The cordycepin complex formulation of claim 1 wherein the purity of the cordycepin polysaccharide is greater than 98%.
7. The cordycepin complex formulation of claim 1 wherein the ginsenoside has a purity of greater than 98%.
8. The cordycepin complex formulation of claim 1 wherein the maca polysaccharide has a purity of greater than 98%.
9. The cordycepin composite preparation of claim 1, wherein the cordycepin composite preparation is in the form of any one of powder, capsule, pill, granule, tablet and oral liquid.
10. The method for preparing the cordycepin composite preparation as claimed in any one of claims 1 to 4, wherein the cordycepin composite preparation is prepared by mixing cordycepin, cordyceps polysaccharide, ginsenoside and maca polysaccharide, adding one or more pharmaceutically acceptable auxiliary materials, and preparing the cordycepin composite preparation by a conventional preparation method of a pharmaceutical preparation.
11. Use of a cordycepin complex formulation of any one of claims 1 to 4 in the preparation of a product for improving exercise fatigue.
12. Use of a cordycepin complex formulation of any one of claims 1 to 4 for the preparation of a product for improving exercise endurance and promoting exercise recovery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311344872.5A CN117224566A (en) | 2023-10-16 | 2023-10-16 | Cordycepin compound preparation, preparation method thereof and application thereof in preparation of sports fatigue improving products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311344872.5A CN117224566A (en) | 2023-10-16 | 2023-10-16 | Cordycepin compound preparation, preparation method thereof and application thereof in preparation of sports fatigue improving products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117224566A true CN117224566A (en) | 2023-12-15 |
Family
ID=89094803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311344872.5A Pending CN117224566A (en) | 2023-10-16 | 2023-10-16 | Cordycepin compound preparation, preparation method thereof and application thereof in preparation of sports fatigue improving products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117224566A (en) |
-
2023
- 2023-10-16 CN CN202311344872.5A patent/CN117224566A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101809172B1 (en) | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component | |
| KR20100111300A (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
| TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| Xianchu et al. | Grape seed proanthocyanidin extract supplementation affects exhaustive exercise-induced fatigue in mice | |
| AU2009216012A1 (en) | Leaves extract of panax SP., a process of making the same and uses thereof | |
| CN113398144B (en) | Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people | |
| WO2012121140A1 (en) | Growth hormone secretion promoter | |
| CN111568945A (en) | Compound cyclocarya paliurus preparation | |
| KR20140089502A (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract | |
| Miura et al. | Antidiabetic effect of nitobegiku in KK-Ay diabetic mice | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| CN117224566A (en) | Cordycepin compound preparation, preparation method thereof and application thereof in preparation of sports fatigue improving products | |
| CN107087795B (en) | Anti-fatigue and anti-anoxia health-care product composition | |
| EP3403664B1 (en) | Use of cistanche tubulosa | |
| CN109157548B (en) | Composition with functions of resisting fatigue and tonifying yang and preparation method thereof | |
| KR101594349B1 (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising processed Panax species plant leaf extract | |
| US7416750B1 (en) | Composition to provide maintenance and nutritional support in glycemic control deficits | |
| CN114468196A (en) | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof | |
| WO2014098295A1 (en) | Composition for preventing or treating oxidative brain damage and brain dysfunction, and production method for same | |
| WO2016206363A1 (en) | Use of jilin ginseng oligopeptide in preparation of anti-oxidant food product or health care food product | |
| CN113575927B (en) | Health-care product composition with neuroprotection and memory improving functions and preparation method thereof | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| JP7409797B2 (en) | Promoting short-chain fatty acid production in the intestinal tract | |
| TW201802106A (en) | Peptide composition and use thereof capable of alleviating and/or preventing liver-related diseases such as fatty liver, liver fibrosis, liver damage and the like |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |